MCID: SPC010
MIFTS: 47

Speech and Communication Disorders

Categories: Mental diseases

Aliases & Classifications for Speech and Communication Disorders

MalaCards integrated aliases for Speech and Communication Disorders:

Name: Speech and Communication Disorders 40 42
Communication Disorder 40 12 15
Language Disorders 54 43 71
Language Disorder 40 12 15
Communication Disorders 54 43
Speech and Language Disorder 71
Speech Language Disorder 40
Speech-Language Disorder 39
Communication Impairment 71

Classifications:



External Ids:

Disease Ontology 12 DOID:2033 DOID:93
NCIt 49 C2958 C97155
SNOMED-CT 67 278919001 62305002
ICD10 32 F80.9
UMLS 71 C0009460 C0023009 C0023015

Summaries for Speech and Communication Disorders

MedlinePlus : 42 Many disorders can affect our ability to speak and communicate. They range from saying sounds incorrectly to being completely unable to speak or understand speech. Causes include Hearing disorders and deafness Voice problems, such as dysphonia or those caused by cleft lip or palate Speech problems like stuttering Developmental disabilities Learning disabilities Autism spectrum disorder Brain injury Stroke Some speech and communication problems may be genetic. Often, no one knows the causes. By first grade, about 5 percent of children have noticeable speech disorders. Speech and language therapy can help. NIH: National Institute on Deafness and Other Communication Disorders

MalaCards based summary : Speech and Communication Disorders, also known as communication disorder, is related to stuttering and alexia, and has symptoms including lethargy, other symbolic dysfunction and aprosodia. An important gene associated with Speech and Communication Disorders is FOXP2 (Forkhead Box P2), and among its related pathways/superpathways is Neuroscience. The drugs Methylprednisolone and Valproic acid have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and eye, and related phenotypes are behavior/neurological and growth/size/body region

Disease Ontology : 12 A communication disorder that involves the processing of linguistic information.

Wikipedia : 74 A communication disorder is any disorder that affects an individual's ability to comprehend, detect, or... more...

Related Diseases for Speech and Communication Disorders

Diseases related to Speech and Communication Disorders via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 257)
# Related Disease Score Top Affiliating Genes
1 stuttering 32.9 FOXP2 CNTNAP2 ASPRV1
2 alexia 32.9 MAPT GRN CBSL ASPRV1 APOE
3 speech disorder 32.9 TOR3A PRODH MAPT KIAA0319 FOXP2 CNTNAP2
4 dyslexia 32.8 TOR3A KIAA0319 IQCB1 FOXP2 CNTNAP2 CELF4
5 expressive language disorder 32.4 TOR3A FOXP2 CEBPD
6 autism 31.3 PRODH MECP2 MAPT FOXP2 CNTNAP2 CELF4
7 landau-kleffner syndrome 31.1 MECP2 CNTNAP2
8 autism spectrum disorder 31.1 PRODH MECP2 FUS FOXP2 CNTNAP2
9 aphasia 31.1 TARDBP MAPT GRN FUS FOXP2 CHMP2B
10 dysgraphia 30.9 TARDBP MAPT GRN CHMP2B CELF4 CBSL
11 agraphia 30.9 TARDBP MAPT IQCB1 GRN CBSL C9orf72
12 echolalia 30.8 TOR3A MECP2 MAPT GRN FOXP2 CNTNAP2
13 attention deficit-hyperactivity disorder 30.7 PRODH MECP2 KIAA0319 FOXP2 CNTNAP2 ADAMTS2
14 fragile x syndrome 30.7 TOR3A TARDBP PRODH MECP2 CNTNAP2
15 learning disability 30.7 PRODH MECP2 MAPT KIAA0319 IQCB1 FOXP2
16 frontotemporal dementia 30.7 TARDBP MAPT GRN FUS CHMP2B C9orf72
17 lateral sclerosis 30.7 TARDBP FUS CHMP2B C9orf72
18 specific language impairment 30.6 TOR3A KIAA0319 IQCB1 FOXP2 CNTNAP2 CELF4
19 progressive non-fluent aphasia 30.6 MAPT GRN CHMP2B C9orf72
20 prosopagnosia 30.6 TARDBP MAPT GRN ASPRV1
21 dyscalculia 30.6 TARDBP PRODH KIAA0319 IQCB1 GRN CHMP2B
22 progressive muscular atrophy 30.5 TARDBP FUS CHMP2B C9orf72
23 amnestic disorder 30.5 MAPT CNTNAP2 APOE
24 dementia 30.5 TARDBP MAPT GRN FUS CHMP2B C9orf72
25 semantic dementia 30.5 TARDBP MAPT GRN CHMP2B C9orf72 APOE
26 prion disease 30.5 TARDBP MAPT APOE
27 akinetic mutism 30.5 TARDBP MAPT
28 associative agnosia 30.5 TARDBP MAPT GRN FUS CHMP2B C9orf72
29 amyotrophic lateral sclerosis 1 30.5 TARDBP PRODH MAPT GRN FUS CHMP2B
30 movement disease 30.4 TARDBP PRODH MAPT GRN FUS CBSL
31 schizophrenia 30.4 PRODH MECP2 MAPT FOXP2 CNTNAP2 C9orf72
32 corticobasal degeneration 30.4 TARDBP MAPT
33 frontotemporal lobar degeneration with tdp43 inclusions, grn-related 30.4 MAPT GRN
34 pervasive developmental disorder 30.4 TOR3A PRODH MECP2 IQCB1 FOXP2 CNTNAP2
35 reading disorder 30.4 TOR3A KIAA0319 IQCB1 FOXP2 CNTNAP2 CELF4
36 supranuclear palsy, progressive, 1 30.3 TARDBP MAPT GRN FUS CHMP2B CBSL
37 pick disease of brain 30.3 TARDBP MAPT GRN FUS CHMP2B CBSL
38 articulation disorder 30.3 FOXP2 CNTNAP2 CEBPD ASPRV1
39 apraxia 30.3 MAPT GRN FOXP2 CNTNAP2 C9orf72 APOE
40 disease of mental health 30.2 TOR3A TARDBP PRODH MECP2 MAPT GRN
41 mutism 30.2 TOR3A MAPT GRN CNTNAP2 CHMP2B C9orf72
42 motor neuron disease 30.2 TARDBP MAPT GRN FUS C9orf72 APOE
43 nominal aphasia 30.1 TARDBP MAPT GRN FUS CHMP2B CBSL
44 foxp2-related speech and language disorders 12.6
45 childhood apraxia of speech 11.7
46 epilepsy-aphasia spectrum 11.5
47 cerebral atrophy 11.2
48 swallowing disorders 11.2
49 cluttering 11.1
50 mixed receptive-expressive language disorder 11.0

Graphical network of the top 20 diseases related to Speech and Communication Disorders:



Diseases related to Speech and Communication Disorders

Symptoms & Phenotypes for Speech and Communication Disorders

UMLS symptoms related to Speech and Communication Disorders:


lethargy, other symbolic dysfunction, aprosodia, neurobehavioral manifestations

MGI Mouse Phenotypes related to Speech and Communication Disorders:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.18 APOE C9orf72 CBSL CEBPD CELF4 CNTNAP2
2 growth/size/body region MP:0005378 10.07 ADAMTS2 APOE C9orf72 CBSL CELF4 CNTNAP2
3 cellular MP:0005384 10.06 APOE C9orf72 CBSL CEBPD CNTNAP2 GATM
4 integument MP:0010771 9.93 ADAMTS2 APOE ASPRV1 C9orf72 CBSL CEBPD
5 liver/biliary system MP:0005370 9.5 APOE C9orf72 CBSL CELF4 GATM GRN
6 nervous system MP:0003631 9.44 APOE C9orf72 CBSL CELF4 CHMP2B CNTNAP2

Drugs & Therapeutics for Speech and Communication Disorders

Drugs for Speech and Communication Disorders (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 96)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
2
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
3
Levetiracetam Approved Phase 4 102767-28-2 441341
4
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
5
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
6
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
7
Oxcarbazepine Approved Phase 4 28721-07-5 34312
8 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
9
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
10
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
11
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
12 Anesthetics Phase 4
13 Analgesics Phase 4
14 Anti-Inflammatory Agents Phase 4
15 Sodium Channel Blockers Phase 4
16 Antineoplastic Agents, Hormonal Phase 4
17 Hypnotics and Sedatives Phase 4
18 Methylprednisolone Acetate Phase 4
19 glucocorticoids Phase 4
20 Analgesics, Non-Narcotic Phase 4
21 Anti-Anxiety Agents Phase 4
22 Anesthetics, General Phase 4
23 Antiemetics Phase 4
24 GABA Modulators Phase 4
25 Anticonvulsants Phase 4
26 Diuretics, Potassium Sparing Phase 4
27 Gastrointestinal Agents Phase 4
28 Anesthetics, Intravenous Phase 4
29 Omega 3 Fatty Acid Phase 4
30
Cycloserine Approved Phase 3 68-41-7 401 6234
31
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
32
Memantine Approved, Investigational Phase 3 19982-08-2 4054
33 Ecopipam Investigational Phase 2, Phase 3 112108-01-7
34 Dopamine Antagonists Phase 2, Phase 3
35 Antipsychotic Agents Phase 2, Phase 3
36 Anti-Infective Agents Phase 3
37 Antitubercular Agents Phase 3
38 Anti-Bacterial Agents Phase 3
39 Antibiotics, Antitubercular Phase 3
40 Antimetabolites Phase 3
41 Dopamine Agents Phase 3
42 Excitatory Amino Acid Antagonists Phase 3
43 Antiparkinson Agents Phase 3
44 Hormones Phase 3
45 Hormone Antagonists Phase 3
46 Estrogen Antagonists Phase 3
47 Estrogen Receptor Antagonists Phase 3
48 Estrogen Receptor Modulators Phase 3
49 Estrogens Phase 3
50 Raloxifene Hydrochloride Phase 3

Interventional clinical trials:

(show top 50) (show all 165)
# Name Status NCT ID Phase Drugs
1 Electroclinical Effect of Diazepam and Steroid in Patients With Benign Childhood Epilepsy With Centrotemporal Spikes Unknown status NCT03490487 Phase 4 conventional antiepileptic drugs;oral steroid;Diazepam
2 Omega 3/6 Fatty Acids for Reading in Children: A Randomised, Double-blind, Placebo-controlled Trial in 9-year-old Mainstream Schoolchildren in Sweden Completed NCT02557477 Phase 4
3 Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech Recruiting NCT01818661 Phase 4 AV-1451
4 An Open-label Study to Evaluate the Efficacy and Tolerability of Ecopipam in Adults With Childhood Onset Fluency Disorder (Stuttering). Unknown status NCT02909088 Phase 2, Phase 3 Ecopipam 50mg;Ecopipam 100mg
5 Effectiveness of a Parent-Based Language Intervention Group Program for Two-Year-Old Children With Language Delay Unknown status NCT00625261 Phase 3
6 A Comparison of Language Intervention Programs Completed NCT00033150 Phase 3
7 A Randomized Controlled Trial of D-Cycloserine in Autism Completed NCT00198120 Phase 3 D-cycloserine;Placebo
8 Use of Acupuncture In Autistic Spectrum Disorder Completed NCT00346736 Phase 3
9 Tinnitus Retraining Therapy Trial Completed NCT01177137 Phase 3
10 Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions: A Randomized-controlled Trial Recruiting NCT03553875 Phase 3 Memantine Hydrochloride;Placebo
11 Raloxifene Augmentation in Patients With a Schizophrenia Spectrum Disorder to Reduce Symptoms and Improve Cognition Recruiting NCT03043820 Phase 3 Raloxifene;Placebo
12 AMALS: Addressing Multiple Aspects of Language Simultaneously: A Randomized Clinical Trial Completed NCT00840060 Phase 2
13 Effects of Intensity of Early Communication Intervention Completed NCT00723151 Phase 2
14 Sulforaphane Treatment of Children With Autism Spectrum Disorder (ASD) Completed NCT02561481 Phase 1, Phase 2 Sulforaphane;Placebo
15 Transcranial Direct Current Stimulation and Aphasia Treatment Outcomes Completed NCT01686373 Phase 2
16 Treating Intention In Aphasia: Neuroplastic Substrates Completed NCT00567242 Phase 1, Phase 2
17 A Phase II, Randomized, Double-blind, Placebo-controlled Study of Myrosinase-enriched Glucoraphanin, a Sulforaphane Precursor System, in Autism Spectrum Disorder Completed NCT02909959 Phase 2 Sulforaphane;Placebo
18 Effect Of Verb Network Strengthening Treatment on Lexical Retrieval in Aphasia Completed NCT01300624 Phase 2
19 Characterization and Sequential Pharmacotherapy of Severe Mood Dysregulation Completed NCT01714310 Phase 2 lisdexamfetamine;Placebo;fluoxetine
20 Maximizing Outcomes for Preschoolers With Developmental Language Disorder: Testing the Effects of a Sequentially Targeted Naturalistic Intervention. Recruiting NCT03782493 Phase 2
21 Word by Word: Building Sentences With Preschoolers Who Use AAC Recruiting NCT03538925 Phase 2
22 Correcting Residual Errors With Spectral, Ultrasound, and Traditional Speech Therapy: A Randomized Controlled Trial Recruiting NCT03737318 Phase 2
23 Treatment of Social and Language Deficits With Leucovorin for Young Children With Autism Not yet recruiting NCT04060030 Phase 2 Levoleucovorin Calcium
24 Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium Not yet recruiting NCT04060017 Phase 2 Levoleucovorin Calcium
25 Leucovorin for the Treatment of Language Impairment in Children With Autism Spectrum Disorder Not yet recruiting NCT02839915 Phase 2 Folinic Acid
26 Head-Mounted Vibrotactile Prosthesis for Patients With Chronic Postural Instability Completed NCT00889824 Phase 1
27 The Effect of Inhaled Corticosteroids on Vocal Fold Nodules in Children: A Pilot Study Recruiting NCT03040596 Phase 1 Fluticasone propionate
28 To Investigate the Event Related Potentials (ERPs) of Patients With Brain Lesions Unknown status NCT01254500
29 Concordance of Pain Detection in Patients by Doloplus® and Algoplus® Behavioural Scales. Unknown status NCT02174744
30 Language and Motricity in Preterm School Age Children Unknown status NCT02811029
31 Oral Language in Children With Down Syndrome: Lexical, Syntactic and Semantic Aspects Unknown status NCT00952354
32 INTERNATIONAL VALIDATION STUDY OF THE ALGOPLUS SCALE IN FIVE LANGUAGES Unknown status NCT02018614
33 Study of the Interest of Proprioceptive Therapy as a Complement to Speech Therapy in Children With Reading Difficulties Unknown status NCT02861599
34 Interest of Combining Speech Therapy With a Non-invasive Brain Stimulation (tDCS) for the Aphasic Patient Unknown status NCT02612753
35 Structural and Functional Connectivity in Autism Spectrum Disorders by Using Diffusion Spectrum Imaging and Functional Magnetic Resonance Imaging Studies Unknown status NCT00755430
36 Clinical and Genetic Study of Autism Spectrum Disorder Unknown status NCT00494754
37 MP-LoGa: Bi-hemispheral Transcranial Direct Current Stimulation to Improve the Severe Aphasia in Subacute Stroke Patients: a Randomized, Placebo-controlled, Double Blinded Multi-center Trial Unknown status NCT02395874
38 Impact of the Use of the Scale ALGOPLUS® on the Prescriptions of Analgesics in Emergency Department on Patients of 75 Years Old or More Unknown status NCT02258503
39 Linguistic, Anatomic/Metabolic and Biologic Characterisation of the Three Main Variants of Primary Progressive Aphasia : Towards the Rationale for Drug Trials and Specific Language Rehabilitations Unknown status NCT02297035
40 Phonological Treatment Paired With Intensive Speech Therapy Promotes Reading Recovery in Chronic Aphasia Unknown status NCT02799017
41 Transcranial Direct Current Stimulation (tDCS) an Adjuvant to Intensive Speech Therapy in Chronic Post Stroke Aphasia Unknown status NCT02801864
42 Using Mobile Health Technology to Optimize Communication Outcomes for South African Children With Developmental Disabilities Completed NCT03409406
43 Pivotal Response Treatment for Individuals With Intellectual Disabilities Completed NCT01988623
44 Evaluation of Mental Flexibility Through Language Tests in Adolescents With Frontal Brain Damage and in Healthy Children in Ages 8-17 Completed NCT01696292
45 Language Stimuli Screening in Children Completed NCT00016796
46 An Efficacy Trial of Milieu Teaching Language Intervention in Children With Language Disorders Completed NCT01975922
47 Assessing the Effectiveness of Communication Therapy in the North West (The ACT NoW Pilot Study) Completed NCT00158106
48 Developmental Language Difficulties: Behavioural and Electrophysiological Studies of the Connections Between Spoken and Written Language and Specificity of These Disorders Completed NCT02872870
49 Experimental Word Learning in Children With Normal Development and Children With Language Impairment Completed NCT00607334
50 Specific Language Impairment (SLI) in Children May Caused by Epileptic Brain Activity Completed NCT04141332

Search NIH Clinical Center for Speech and Communication Disorders

Cochrane evidence based reviews: communication disorders

Genetic Tests for Speech and Communication Disorders

Anatomical Context for Speech and Communication Disorders

MalaCards organs/tissues related to Speech and Communication Disorders:

40
Brain, Testes, Eye, Tongue, Cortex, Thalamus, Temporal Lobe

Publications for Speech and Communication Disorders

Articles related to Speech and Communication Disorders:

(show top 50) (show all 1691)
# Title Authors PMID Year
1
Respiratory muscle training in stroke patients with respiratory muscle weakness, dysphagia, and dysarthria - a prospective randomized trial. 42
32150072 2020
2
Longitudinal study of the development of obstruent correctness from ages 3 to 5 years in 108 Danish children with unilateral cleft lip and palate: a sub-study within a multicentre randomized controlled trial. 42
31710176 2020
3
Clinical Trial for Stuttering Treatment: pilot study about dog participation in the therapy session. 42
31721913 2019
4
Recent advances in the genetics of language impairment. 54 61
20193051 2010
5
Assessing the impact of FOXP1 mutations on developmental verbal dyspraxia. 61 54
19352412 2009
6
FOXP genes, neural development, speech and language disorders. 61 54
20429420 2009
7
High-throughput analysis of promoter occupancy reveals direct neural targets of FOXP2, a gene mutated in speech and language disorders. 61 54
17999362 2007
8
Identification of the transcriptional targets of FOXP2, a gene linked to speech and language, in developing human brain. 61 54
17999357 2007
9
Mutation screening of FOXP2 in individuals diagnosed with autistic disorder. 54 61
12655497 2003
10
Preoperative augmentative and alternative communication enhancement in pediatric tracheostomy. 61
31487042 2020
11
Screening for the Identification of Oral Language Difficulties in Brazilian Preschoolers: A Validation Study. 61
32496867 2020
12
A Multidisciplinary Delphi Consensus Study of Communicative Participation in Young Children With Language Disorders. 61
32543956 2020
13
Development and diagnostic validation of the Brisbane Evidence-Based Language Test. 61
32571105 2020
14
Validation of the Early Language Scale. 61
32533257 2020
15
Delirium after cardiac arrest: Phenotype, prediction, and outcome. 61
32276001 2020
16
A Systematic Review of Academic Discourse Interventions for School-Aged Children With Language-Related Learning Disabilities. 61
32525756 2020
17
Fat embolism syndrome with cerebral fat embolism through a patent foramen ovale: A case report. 61
32541485 2020
18
Overcoming Speech and language disorders in acute and critical care: 40 years later. 61
32305145 2020
19
The generalisation of linguistic constructions in children with or without developmental language disorders. 61
32423494 2020
20
Perception of Medial Consonants by Children With and Without Speech and Language Disorders: A Preliminary Study. 61
32293902 2020
21
Psychometric properties of the mandarin clinical evaluation of language for preschooler's core scale. 61
32535376 2020
22
"Tell Me About Your Child": A Grounded Theory Study of Mothers' Understanding of Language Disorder. 61
32348158 2020
23
Parent concerns: Differentiating developmental diagnoses in young children. 61
32454302 2020
24
ASPM-lexical tone association in speakers of a tone language: Direct evidence for the genetic-biasing hypothesis of language evolution. 61
32537487 2020
25
Children with language delay referred to Dutch speech and hearing centres: caseload characteristics. 61
32459389 2020
26
Examining the Role of Language in Play Among Children With and Without Developmental Disabilities. 61
32402229 2020
27
[MERS type II mimicking leukoencephalopathy was suspected to be associated with mycoplasma pneumonia infection]. 61
32307392 2020
28
Language ability and adult homelessness. 61
31925870 2020
29
Development of a Digital Content-Free Speech Analysis Tool for the Measurement of Mental Health and Follow-Up for Mental Disorders: Protocol for a Case-Control Study. 61
32406862 2020
30
Defining language disorders in children and adolescents with Noonan Syndrome. 61
32059087 2020
31
Temporal variant of frontotemporal dementia in C9orf72 repeat expansion carriers: two case studies. 61
32180125 2020
32
Prevalence and Incidence of Developmental Disorders in Korea: A Nationwide Population-Based Study. 61
32347466 2020
33
Is atypical rhythm a risk factor for developmental speech and language disorders? 61
32244259 2020
34
Morphological Errors in Monolingual Spanish-Speaking Children With and Without Developmental Language Disorders. 61
32255752 2020
35
Understanding event-related potentials (ERPs) in clinical and basic language and communication disorders research: a tutorial. 61
32347637 2020
36
Treating Deficits in Auditory Processing Abilities. 61
32004103 2020
37
Focused Stimulation Intervention in 4- and 5-Year-Old Children With Developmental Language Disorder: Exploring Implementation in Clinical Practice. 61
32255743 2020
38
Altered efficiency of white matter connections for language function in children with language disorder. 61
32004807 2020
39
Does the cerebellar sequential theory explain spoken language impairments? A literature review. 61
32290716 2020
40
The Complex Relation between Executive Functions and Language in Preschoolers with Developmental Language Disorders. 61
32182903 2020
41
Validation of a case definition for speech and language disorders: In community-dwelling older adults in Alberta. 61
32165481 2020
42
Incidence of frontotemporal disorders in Olmsted County: A population-based study. 61
31784373 2020
43
Assessment of implicit language and theory of mind in multiple sclerosis. 61
31586684 2020
44
Sex Differences in Functional Brain Networks for Language. 61
31512720 2020
45
Play Sports for a Quieter Brain: Evidence From Division I Collegiate Athletes. 61
31813316 2020
46
Cortical Foxp2 Supports Behavioral Flexibility and Developmental Dopamine D1 Receptor Expression. 61
31711176 2020
47
Speech and Language Disorders in Friedreich Ataxia: Highlights on Phenomenology, Assessment, and Therapy. 61
31701351 2020
48
Western Aphasia Battery-Revised Profiles in Primary Progressive Aphasia and Primary Progressive Apraxia of Speech. 61
31639312 2020
49
Psychiatric and Medical Profiles of Autistic Adults in the SPARK Cohort. 61
32096123 2020
50
The Association of Dyslexia and Developmental Speech and Language Disorder Candidate Genes with Reading and Language Abilities in Adults. 61
32248883 2020

Variations for Speech and Communication Disorders

Expression for Speech and Communication Disorders

Search GEO for disease gene expression data for Speech and Communication Disorders.

Pathways for Speech and Communication Disorders

Pathways related to Speech and Communication Disorders according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.56 TARDBP MECP2 MAPT CNTNAP2 APOE

GO Terms for Speech and Communication Disorders

Cellular components related to Speech and Communication Disorders according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 dendrite GO:0030425 9.35 MAPT FUS CNTNAP2 C9orf72 APOE
2 axolemma GO:0030673 9.16 MAPT CNTNAP2
3 main axon GO:0044304 8.62 MAPT C9orf72

Biological processes related to Speech and Communication Disorders according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.62 TARDBP MECP2 MAPT APOE
2 stress granule assembly GO:0034063 9.37 MAPT C9orf72
3 multicellular organismal response to stress GO:0033555 9.26 MECP2 KIAA0319
4 neuron projection development GO:0031175 9.26 MECP2 MAPT CNTNAP2 APOE
5 vocal learning GO:0042297 9.16 FOXP2 CNTNAP2
6 gene expression GO:0010467 8.8 TARDBP FUS APOE

Molecular functions related to Speech and Communication Disorders according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lipoprotein particle binding GO:0071813 8.62 MAPT APOE

Sources for Speech and Communication Disorders

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....